The FDA's Pharmacy Compounding Advisory Committee is meeting this week to decide whether to allow compounding pharmacies to produce popular peptide injections that are heavily marketed for muscle recovery and longevity. This is a significant regulatory moment — peptides currently exist in a gray area, popular with wellness influencers and some doctors but lacking clinical evidence of effectiveness in humans, and the Trump administration's drug regulators will signal how they plan to handle this growing market. The controversy extends beyond the peptides themselves: industry groups argue that compounding oversight would improve safety and quality, but critics have flagged concerns about the advisory panel's composition and potential conflicts of interest.